Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis

Wang, Peile; Liu, Shaohua; Sun, Tongwen; Yang, Jing

doi:10.1016/j.ijantimicag.2024.107099

International Journal of Antimicrobial Agents

2024

DOI: 10.1016/j.ijantimicag.2024.107099

|View full text |Cite

Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis

Peile Wang,

Shaohua Liu,

Tongwen Sun

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

How can polymyxin B be dosed based on current pharmacokinetic knowledge?

Chen,

Zhang,

2024

Eur J Clin Pharmacol

View full text Add to dashboard Cite

How can polymyxin B be dosed based on current pharmacokinetic knowledge?

Chen,

Zhang,

2024

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The Impact of Spironolactone Co-administration on Cyclosporin Initial Dosage Optimization for Pediatric Refractory Nephrotic Syndrome

Han,

Rui,

Yang

et al. 2024

CPD

View full text Add to dashboard Cite

Objectives: Cyclosporin has been used for the treatment of pediatric refractory nephrotic syndrome (PRNS). However, the narrow therapeutic window and large pharmacokinetic variability make it difficult to individualize cyclosporin administration. Meanwhile, spironolactone has been reported to affect cyclosporin metabolism in PRNS patients. This study aims to explore the initial dosage optimization of cyclosporin in PRNS based on the impact of spironolactone co-administration. Methods: Monte Carlo simulation based on a previously established cyclosporin population pharmacokinetic model for PRNS was used to design cyclosporin dosing regimen. Results: In this study, the probability of drug concentration reaching the target and the convenience of times of administration were considered comprehensively. The optimal administration regimen in PRNS without spironolactone was 6, 5, 4 and 3 mg/kg cyclosporin split into two doses for the body weight of 5-8, 8-18, 18-46 and 46-70 kg, respectively. The optimal administration regimen in PRNS with spironolactone was 4, 3, 2 mg/kg cyclosporin split into two doses for body weight of 5-14, 14-65, and 65-70 kg, respectively. Conclusion: The cyclosporin dosing regimen for PRNS based on Monte Carlo simulation was systematically developed and the initial dosage optimization of cyclosporin in PRNS was recommended for the first time.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis

Cited by 2 publications

References 36 publications

How can polymyxin B be dosed based on current pharmacokinetic knowledge?

How can polymyxin B be dosed based on current pharmacokinetic knowledge?

The Impact of Spironolactone Co-administration on Cyclosporin Initial Dosage Optimization for Pediatric Refractory Nephrotic Syndrome

Contact Info

Product

Resources

About